益气开秘方联合生物反馈治疗功能性便秘伴直肠低敏感的临床疗效观察

注册号:

Registration number:

ITMCTR2200006103

最近更新日期:

Date of Last Refreshed on:

2022-06-12

注册时间:

Date of Registration:

2022-06-12

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

益气开秘方联合生物反馈治疗功能性便秘伴直肠低敏感的临床疗效观察

Public title:

Clinical Study on Yiqi Kaimi Recipe Combined with Biofeedback in the Treatment of Functional Constipation with Rectal Hyposensitivity

注册题目简写:

English Acronym:

研究课题的正式科学名称:

益气开秘方联合生物反馈治疗功能性便秘伴直肠低敏感的临床疗效观察

Scientific title:

Clinical Study on Yiqi Kaimi Recipe Combined with Biofeedback in the Treatment of Functional Constipation with Rectal Hyposensitivity

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200060820 ; ChiMCTR2200006103

申请注册联系人:

姚一博

研究负责人:

王琛

Applicant:

Yibo Yao

Study leader:

Wang Chen

申请注册联系人电话:

Applicant telephone:

+86 13774320630

研究负责人电话:

Study leader's telephone:

+86 18917763340

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yibo.yao@shutcm.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

wangchen_longhua@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区宛平南路725号

研究负责人通讯地址:

上海市徐汇区宛平南路725号

Applicant address:

725 Wanping Road South, Xuhui District, Shanghai

Study leader's address:

725 Wanping Road South, Xuhui District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学附属龙华医院

Applicant's institution:

Longhua Hospital Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2021LCSY087

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海中医药大学附属龙华医院伦理委员会

Name of the ethic committee:

Institutional Review Board, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2021/7/29 0:00:00

伦理委员会联系人:

刘胜

Contact Name of the ethic committee:

Liu Sheng

伦理委员会联系地址:

上海市徐汇区宛平南路725号

Contact Address of the ethic committee:

725 Wanping Road South, Xuhui District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属龙华医院

Primary sponsor:

Longhua Hospital Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市徐汇区宛平南路725号

Primary sponsor's address:

725 Wanping Road South, Xuhui District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

中国

Province:

上海

City:

单位(医院):

上海中医药大学附属龙华医院

具体地址:

徐汇区宛平南路725号

Institution
hospital:

上海中医药大学龙华医院

Address:

徐汇区宛平南路725号

经费或物资来源:

上海市临床重点专科(shslczdzk04301)

Source(s) of funding:

Shanghai key clinical specialties(shslczdzk04301)

研究疾病:

功能性便秘伴直肠低敏感型

研究疾病代码:

Target disease:

functional constipation with rectal hyposensitivity

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

通过前瞻性、随机对照的研究方法,以功能性便秘伴有直肠低敏感的患者为观察对象,采用益气开秘方联合生物反馈进行治疗,观察治疗前后采集肛门直肠测压、感觉阈值、胃肠电图、便秘症状积分(CCS)、便秘症状自评问卷(PAC-SYM)以及便秘生存质量量表(PAC-QOL)指标,评价益气开秘方联合生物反馈治疗功能性便秘伴有直肠低敏感患者的有效性、安全性。

Objectives of Study:

The patients with functional constipation and rectal hyposensitivity will be observed by prospective, randomized and controlled research method. Yiqi Kaimi Recipe combined with biofeedback will be used for treatment. Anorectal manometry, sensation threshold, gastrointestinal electrogram and questionnaires(CCS,PAC-SYM and PAC-QOL) were collected before and after treatment in order to evaluate the effectiveness and safety.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合功能性便秘的西医诊断标准; (2)符合中医气阴两虚证辨证标准; (3)病程不限; (4)年龄18周岁~80周岁的(性别不限)患者; (5)已经签署知情同意书的患者。 附: 西医诊断标准: 一、符合功能性便秘罗马Ⅳ诊断标准: (1)必须包括下列两项或两项以上: a.1/4以上的排便感到费力 b. 1/4以上的排便为硬块状或硬便(Bristol粪便性状量表1-2型) c.1/4以上的排便有不尽感 d.1/4以上的排便有肛门直肠梗阻/堵塞感 e.1/4以上的排便需要手法辅助(如用手指协助排便) f.每周自发排便少于3次 (2)不用泻剂时很少出现稀粪; (3)不符合便秘型肠易激综合征的诊断标准。 诊断症状出现至少6个月,近3个月符合以上诊断标准。 二、直肠低敏感诊断标准: 直肠感觉测定:最小感觉阈值>20ml,初始排便阈值>60ml或最大耐受阈值>250ml,三者符合一种或多种。 中医证候诊断标准: 符合气阴两虚证的中医证候,诊断标准《慢性便秘中医诊疗共识意见》中肺脾气虚证及津亏血少证。

Inclusion criteria

(1) Diagnostic with functional constipation by Rome Ⅳ;and Diagnostic with low rectal sensitivity:Rectal sensation measurement: the minimum sensation threshold is more than 20ml, the initial defecation threshold is more than 60ml or the maximum tolerance threshold is more than 250ml, which meet one or more requirements. (2) syndrome with Qi and yin deficiency in traditional Chinese medicine; (3) Unlimited course of disease; (4) Patients aged from 18 to 80 (regardless of gender); (5) Patients who have signed informed consent. v

排除标准:

(1)不符合诊断标准和纳入标准者。 (2)存在肠道恶性病变,或肛周急性感染、出血类疾病。 (3)合并有心血管、脑血管、肝、肾和造血系统等严重原发性疾病,精神病患者。 (4)糖尿病患者血糖控制不理想者(空腹血糖>7.8mmol/L)。 (5)合并严重感染,病情危重患者。 (6)妊娠或哺乳期妇女,过敏体质或肝功能异常者。 (7)根据研究者判断,具有降低入组可能性或使入组复杂化的其他病史,如工作环境经常变动,容易造成失访的情况。 (8)正在参加其他药物临床研究的受试者。

Exclusion criteria:

(1) Excluding those who do not meet the diagnostic criteria and inclusion criteria. (2) There are malignant intestinal lesions, or perianal acute infection and bleeding diseases. (3) There are serious diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system, and psychiatric patients. (4) diabetic patients with impaired glucose control (fasting blood glucose > 7.8mmol/L). (5) Patients with severe infection and critical condition. (6) Pregnant or lactating women, allergic constitution or abnormal liver function. (7) According to the judgment of the researcher, other medical histories that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment, are easy to cause loss of follow-up. (8) Subjects participating in clinical studies of other drugs.

研究实施时间:

Study execute time:

From 2022-06-01

To      2023-05-31

征募观察对象时间:

Recruiting time:

From 2022-06-01

To      2023-05-31

干预措施:

Interventions:

组别:

聚乙二醇组

样本量:

35

Group:

Polyethylene glycol 4000

Sample size:

干预措施:

聚乙二醇4000散

干预措施代码:

Intervention:

Polyethylene glycol 4000

Intervention code:

组别:

益气开秘方组

样本量:

35

Group:

Yiqi Kaimi Recipe

Sample size:

干预措施:

益气开秘方

干预措施代码:

Intervention:

Yiqi Kaimi Recipe

Intervention code:

组别:

益气开秘方组联合生物反馈组

样本量:

35

Group:

Yiqi Kaimi Recipe + biofeedback

Sample size:

干预措施:

益气开秘方组联合生物反馈组

干预措施代码:

Intervention:

Yiqi Kaimi Recipe combined with biofeedback

Intervention code:

样本总量 Total sample size : 105

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

单位级别:

三级甲等

Institution/hospital:

Longhua Hospital Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

便秘患者生存质量量表

指标类型:

次要指标

Outcome:

Patient assessment of constipation quality of life

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

便秘患者症状自评问卷

指标类型:

次要指标

Outcome:

Patient assessment of constipation symptom, PAC-SYM

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃肠肌电

指标类型:

次要指标

Outcome:

Gastrointestinal electromyography

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

直肠感觉功能

指标类型:

次要指标

Outcome:

Rectal sensation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

便秘症状积分

指标类型:

主要指标

Outcome:

Cleveland clinic score, CCS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肛门直肠测压

指标类型:

次要指标

Outcome:

Anorectal manometry

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

Fecal

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood samples

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由专业统计人员采用随机数字表法生成随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Professional statisticians use the random number table method to generate random sequences

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023.9 临床实验网站

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

clinnical trial

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统